Neoadjuvant Intralesional Targeted Immunocytokines (Daromun) in Stage III Melanoma

Skin Cancer

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

J Clin Oncol

Lodde GC, Hassel JC, von Wasielewski I, Meier F, Mohr P, Kähler K, Hauschild A, Glutsch V, Stege H, Berking C, Hüning S, Huynh J, Gutzmer R, Reinhardt L, Schilling B, Loquai C, Erdmann M, Stang A, Kowall B, Galetzka W, Roesch A, Tilkorn D, Ugurel S, Zimmer L, Schadendorf D, Forschner A, Livingstone E

doi: 10.1200/JCO-24-02776

Skin Cancer

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Ann Oncol

Rawson RV, Maher NG, Menzies AM, Lo SN, Ardakani NM, Jackett LA, Vergara IA, Pennington TE, Shannon KF, Ch'ng S, Gonzalez M, Burton EM, Lucas MW, Reijers ILM, Rozeman EA, Gyorki DE, Sandhu S, Carlino MS, Howle J, Khattak M, Van der Westhuizen A, Andrews MC, Atkinson V, van Akkooi ACJ, Spillane AJ, Saw RPM, van de Wiel BA, Blank CU, Long GV, Tetzlaff MT, Scolyer RA

doi: 10.1016/j.annonc.2025.10.1237

Skin Cancer

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

N Engl J Med

Ascierto PA, Del Vecchio M, Merelli B, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Gaudy-Marqueste C, Pigozzo J, Márquez-Rodas I, Butler MO, Di Giacomo AM, Gligich O, De La Cruz-Merino L, Arenberger P, Atkinson V, Nathan P, Hill A, Millward M, Fecher LA, Khushalani NI, Queirolo P, Soomro R, Rathod D, Askelson M, Pe Benito M, Joseph D, Larkin J

doi: 10.1056/NEJMoa2504966

Skin Cancer

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Eur J Cancer

Boutros A, Taylor AM, Li I, Adegoke NA, Wong T, Varey AHR, Shannon KF, Ch'ng S, Saw RPM, Pennington T, Stretch J, Spillane A, van Akkooi ACJ, Scolyer RA, Pires da Silva I, Carlino MS, Long GV, Lo SN, Menzies AM

doi: 10.1016/j.ejca.2025.115782

Skin Cancer

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

Lancet Oncol

Syeda MM, Long GV, Garrett J, Atkinson V, Santinami M, Schadendorf D, Hauschild A, Millward M, Mandala M, Chiarion-Sileni V, Smylie M, Manikhas GM, Dummer R, Wiggins JM, Ali S, Adnaik SB, Tan M, Dajee M, Polsky D

doi: 10.1016/S1470-2045(25)00139-1

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Lung, Respiratory and Thoracic Cancer

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

JAMA Oncol

Ricciuti B, Fusco F, Cooper A, Garbo E, Pecci F, Aldea M, Wang X, Mayoral Penalva M, Ginsberg M, Sholl LM, Nishino M, Di Federico A, Shaverdian N, Bott M, Santo V, Rendina E, Trisolini R, Ramella S, Gallina F, Melis E, Buglioni S, Minuti G, Landi L, Ugalde Figueroa PA, Shaw AT, Chaft J, Awad MM, Cappuzzo F

doi: 10.1001/jamaoncol.2025.1115

Breast Cancer

Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study

Int J Cancer

Andour L, Kroep JR, Putter H, Tollenaar RAEM, Mesker WE, Straver ME

doi: 10.1002/ijc.70219

Gynecologic Cancer

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis

Eur J Cancer

Secchi M, Signorelli M, Rulli E, Maruccio M, Di Martino G, Spadaro D, Giudice E, Turinetto M, Landoni F, Restaino S, Vizzielli G, Martinelli F, Lorusso D

doi: 10.1016/j.ejca.2025.116116

Related content

Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients

Pathological response calculation assessment remains accurate with reduced tumor bed examination following neoadjuvant immunotherapy in clinically detectable stage III melanoma

Nivolumab for Resected Stage III or IV Melanoma at 9 Years

A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma

Clinical validation of droplet digital PCR assays in detecting BRAF(V600)-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung Cancer

Neoadjuvant endocrine therapy often leads to breast and axilla-conserving surgery in stages II and III hormone receptor-positive breast cancer patients: A registry study

Neoadjuvant chemotherapy followed by interval surgery versus primary debulking surgery in FIGO stage III-IV epithelial ovarian cancer: A systematic review and meta-analysis